secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193125-24-133759
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q1 revenue $3.8B (+4% YoY), non-GAAP EPS $0.48, reaffirms FY24 guidance
----------------------------------------------------------------------------

- Revenue $3.819B (+4% YoY, +5% local currency); generics up 9% globally.
- AUSTEDO U.S. sales up 67% YoY; AJOVY $113M (+18% YoY).
- Non-GAAP diluted EPS $0.48 (vs $0.40); GAAP loss per share $0.12 (vs $0.20 loss).
- FY2024 guidance reaffirmed: revenue $15.7-16.3B, non-GAAP EPS $2.20-2.50, free cash flow $1.7-2.0B.
- Positive Phase 3 efficacy results for olanzapine LAI (TEV-749) for schizophrenia; no PDSS observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312524133759/0001193125-24-133759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312524133759/d801848d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-133759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer